TNBC and human epidermal growth factor receptor 2 (HER2)-positive breast cancers are perceived as being more immunogenic compared to luminal breast cancers based on a higher mutational burden, higher tumor-infiltrating lymphocyte (TIL) rates and higher PD-L1 expression (7–10). This evidence concerns the gene CD274 and breast carcinoma.